ReviewFrontiers in endocrinology2025
Exploring the therapeutic potential of phytochemicals apigenin and ellagic acid in managing polycystic ovarian syndrome and its comorbidities: a comprehensive review.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic Ovarian Syndrome (PCOS) is a complex endocrine and metabolic disorder affecting women of reproductive age, characterized by hyperandrogenism, insulin resistance, chronic inflammation, and ovulatory dysfunction. Conventional therapies, such as oral contraceptives, insulin sensitizers, and anti-androgens, primarily offer symptomatic relief and are often associated with chronic adverse effects, underscoring the need for safer and more holistic alternatives. Naturally occurring bioactives have emerged as promising adjunct or alternative therapeutic agents in this context. This review critically examines the therapeutic potential of two phytochemicals or natural bioactives, apigenin and ellagic acid, in the integrative management of PCOS and its associated metabolic disturbances and comorbidities. Apigenin, a flavonoid abundantly present in parsley, chamomile, and citrus fruits, and ellagic acid, a polyphenol found in pomegranates and berries, both demonstrate significant anti-inflammatory, antioxidant, insulin-sensitizing, and anti-androgenic activities. Mechanistic studies reveal their ability to regulate ovarian steroidogenesis, suppress pro-inflammatory cytokines, improve insulin sensitivity via the PI3K/Akt signaling pathway, and reduce hyperandrogenism by inhibiting 5α-reductase. Preclinical and preliminary clinical studies support the efficacy of these treatments in restoring ovarian morphology, normalizing hormonal profiles, and ameliorating metabolic dysfunctions in PCOS models. Although limited by poor bioavailability, both compounds exhibit favorable safety and metabolic profiles, and emerging formulation approaches such as nano-delivery systems, phytosomes, and liposomes offer promising strategies to enhance their clinical applicability. This review advocates incorporating apigenin and ellagic acid into integrative PCOS treatment strategies. It highlights the need for well-designed clinical trials to validate efficacy, establish standardized dosing, and develop advanced delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.